ANTIPHOSPHOLIPID SYNDROME (APS)
Clinical trials for ANTIPHOSPHOLIPID SYNDROME (APS) explained in plain language.
Never miss a new study
Get alerted when new ANTIPHOSPHOLIPID SYNDROME (APS) trials appear
Sign up with your email to follow new studies for ANTIPHOSPHOLIPID SYNDROME (APS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental cell therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and Sjogren's syndrome. Participants receive a single infusion of these specially designed cells. The main goal is to see if the treatment is safe, and res…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 09:19 UTC
-
New drug targets immune attack in six diseases
Disease control Recruiting nowThis early-stage trial tests a new drug called RAY121 in 144 adults with one of six immune diseases: antiphospholipid syndrome, bullous pemphigoid, Behçet's syndrome, dermatomyositis, immune-mediated necrotizing myopathy, or immune thrombocytopenia. The drug blocks a part of the …
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated May 26, 2026 09:03 UTC
-
Experimental cell therapy targets tough autoimmune cases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in about 18 adults with autoimmune diseases like lupus or scleroderma that have not responded to standard therapies. Participants receive a single infusion of these modified immune cells. The main goal is to check sa…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 09:01 UTC
-
Which blood thinner works best for APS patients? new study aims to find out
Knowledge-focused Recruiting nowThis study looks at two types of blood thinners (DOACs and VKAs) to see which is better at preventing repeat blood clots in people with a low-risk form of antiphospholipid syndrome (APS). APS is an autoimmune condition that raises the risk of dangerous clots. The study will follo…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Sponsor: Infanta Leonor University Hospital • Aim: Knowledge-focused
Last updated May 22, 2026 14:03 UTC
-
New study tracks blood clot risks in rare autoimmune disease
Knowledge-focused Recruiting nowThis study follows 200 adults with antiphospholipid syndrome (APS), a rare condition that increases blood clot risk. Researchers will track how often clots return and look at side effects from current treatments. The goal is to update old data and better understand real-world out…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Apr 24, 2026 16:06 UTC